Last edition
News about
Sentynl Appoints myTomorrows as Global Provider to Expand Managed Access Program
Sentynl Therapeutics, a biopharmaceutical company based in the USA and wholly owned by Zydus Lifesciences, has appointed myTomorrows as the global provider for its Managed Access Program (MAP).
MMV Joins iiCON to Boost Infectious Disease Drug Research and Manufacturing Innovation
iiCON, led by the Liverpool School of Tropical Medicine (LSTM), is a global infectious disease R&D programme that unites industry, academic institutions, and clinical bodies to accelerate the development of treatments, diagnostics, and prevention technologies for infectious diseases. Its mission is to save and improve lives.
AST and Marchesini Group Partner to Expand Global Market Presence
AST and Marchesini Group have formed a strategic partnership to strengthen their global market presence by combining technology and expertise in aseptic manufacturing. The collaboration aims to accelerate growth and enhance advanced, sterile production capabilities for customers worldwide.
Veritiv Unveils First Curbside-Recyclable Pallet Shipper for Biopharma Cold Chain
Veritiv has launched PalletShield, the industry’s first curbside-recyclable pallet shipper built for biopharmaceutical cold chain needs. Engineered for the stringent demands of life sciences and healthcare logistics, the solution offers a sustainable alternative to EPS and PUR systems while streamlining pack-outs and reducing disposal costs.
Eli Lilly Expands USA Manufacturing with Alabama Plant
The site will focus on producing synthetic and peptide-based medicines, including Lilly’s first oral GLP-1 weight-loss therapy, Orforglipron, which the company expects to submit for regulatory approval early next year.
Government's Price Control Measures on Pharma Products Deliver Annual Savings of INR 25,000 Crore
The National Pharmaceutical Pricing Authority (NPPA) has fixed ceiling prices for 935 scheduled formulations as of early December, resulting in estimated annual savings of around INR 3,802 crore for the public.
Xcell Biosciences and Culture Biosciences Partner to Improve Cell Therapy Quality with AI and ML
Xcell Biosciences has partnered with Culture Biosciences to integrate AI- and ML-driven analytics into cell therapy development. The collaboration leverages a cloud-based platform capable of multivariate analysis, enabling real-time optimisation to enhance cell therapy performance and improve patient outcomes.
Novo Nordisk Completes Acquisition of Akero Therapeutics
Novo Nordisk has finalised its acquisition of Akero Therapeutics, making Akero a wholly owned subsidiary. Following the transaction, Akero’s common stock will cease trading on the Nasdaq Global Select Market.
This designation underscores Japan’s commitment to accelerating breakthrough therapies that demonstrate novel mechanisms of action, strong preliminary data, and meaningful potential for addressing severe, underserved conditions.
FDA Qualifies First AI Tool to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified the world’s first artificial intelligence tool designed to speed up drug development for liver disease.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy